Literature DB >> 36261847

TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Ning Huang1,2, Xiaolin Sun1, Peng Li1, Xin Liu1,2, Xuemei Zhang3, Qian Chen4, Hong Xin5.   

Abstract

The tripartite-motif (TRIM) family represents one of the largest classes of putative single protein RING-finger E3 ubiquitin ligases. TRIM family is involved in a variety of cellular signaling transductions and biological processes. TRIM family also contributes to cancer initiation, progress, and therapy resistance, exhibiting oncogenic and tumor-suppressive functions in different human cancer types. Moreover, TRIM family members have great potential to serve as biomarkers for cancer diagnosis and prognosis. In this review, we focus on the specific mechanisms of the participation of TRIM family members in tumorigenesis, and cancer development including interacting with dysregulated signaling pathways such as JAK/STAT, PI3K/AKT, TGF-β, NF-κB, Wnt/β-catenin, and p53 hub. In addition, many studies have demonstrated that the TRIM family are related to tumor resistance; modulate the epithelial-mesenchymal transition (EMT) process, and guarantee the acquisition of cancer stem cells (CSCs) phenotype. In the end, we havediscussed the potential of TRIM family members for cancer therapeutic targets.
© 2022. The Author(s).

Entities:  

Keywords:  CSCs; Cancer; Cancer resistance; EMT; Signaling pathway; TRIM family; Tumorigenesis

Year:  2022        PMID: 36261847      PMCID: PMC9583506          DOI: 10.1186/s40164-022-00322-w

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN: 2162-3619


  281 in total

Review 1.  Ubiquitin and ubiquitin-like proteins as multifunctional signals.

Authors:  Rebecca L Welchman; Colin Gordon; R John Mayer
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

2.  Knockdown of TRIM47 inhibits breast cancer tumorigenesis and progression through the inactivation of PI3K/Akt pathway.

Authors:  Yaqiu Wang; Can Liu; Zhihui Xie; Hong Lu
Journal:  Chem Biol Interact       Date:  2020-01-22       Impact factor: 5.192

Review 3.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

4.  Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion.

Authors:  Linlin Li; Lei Dong; Xiaotong Qu; Shi Jin; Xiupeng Lv; Guang Tan
Journal:  Int J Oncol       Date:  2016-02-17       Impact factor: 5.650

Review 5.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

6.  TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability.

Authors:  Mei Ping; Shumin Wang; Yarong Guo; Junmei Jia
Journal:  Biochem Biophys Res Commun       Date:  2021-11-29       Impact factor: 3.575

7.  Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.

Authors:  Yanyan Ma; Zengtao Wei; Robert C Bast; Zhanying Wang; Yan Li; Meng Gao; Yanping Liu; Xiaoyan Wang; Chun Guo; Lining Zhang; Xiaoyan Wang
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

9.  Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-β signaling.

Authors:  Nianfeng Sun; Yu Xue; Ting Dai; Xiding Li; Nanxiang Zheng
Journal:  Biosci Rep       Date:  2017-07-12       Impact factor: 3.840

10.  TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway.

Authors:  Ye Sun; Bing Ji; Yifei Feng; Yue Zhang; Dongjian Ji; Chunyan Zhu; Sen Wang; Chuan Zhang; Dongsheng Zhang; Yueming Sun
Journal:  Oncol Rep       Date:  2017-05-22       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.